All the news Showing 10 of 36 articles from: Hepatocellular carcinoma (HCC)Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Just 18% of people with hepatitis/HIV co-infection and cirrhosis are screened for liver cancer as often as recommended Roger Pebody / 11 June 2019 There is a “strikingly low adherence” to clinical guidelines for ultrasound screening for hepatocellular carcinoma in Western Europe, researchers report in the Journal of Viral Hepatitis.Over years or decades, chronic hepatitis B ... Higher HIV viral load and lower CD4 count linked to liver cancer risk Liz Highleyman / 14 March 2019 People living with HIV who have a longer duration of detectable viral load and those with low CD4 cell counts have a higher likelihood of developing liver cancer in the absence of ... DAA treatment reduces the risk of death and liver cancer in France Keith Alcorn / 12 February 2019 Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ... HIV infection an independent risk factor for poorer survival from liver cancer Michael Carter / 28 January 2019 Infection with HIV is associated with significantly worse survival for people with hepatocellular carcinoma (HCC, the most common type of primary liver cancer), according to findings from a large international cohort study published in ... Nivolumab works well for liver cancer patients with advanced disease Liz Highleyman / 26 November 2018 Nivolumab (Opdivo), a checkpoint inhibitor that helps the immune system fight cancer, was associated with tumour shrinkage or disease stabilisation in just over half of hepatocellular carcinoma (HCC) patients with substantial liver function ... Aspirin use associated with lower risk of liver cancer Liz Highleyman / 13 November 2018 Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ... US FDA approves pembrolizumab immunotherapy for liver cancer Liz Highleyman / 12 November 2018 The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ... Ramucirumab targeted therapy extends liver cancer survival Liz Highleyman / 09 July 2018 Ramucirumab (Cyramza), a type of targeted therapy that slows tumour growth by blocking blood vessel formation, led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma ... T cell immunotherapy shows promise for treating liver cancer Liz Highleyman / 22 May 2018 Personalised immunotherapy reduces the risk of liver cancer recurrence and may lead to tumour regression, according to a pair of studies presented at the 2018 International Liver Congress last month in Paris. In ... Large Italian studies confirm no increase in liver cancer risk after hepatitis C treatment Keith Alcorn / 19 April 2018 Further research presented at this year’s International Liver Congress confirms that direct-acting antiviral (DAA) treatment leading to the cure of hepatitis C infection does not raise the risk of developing ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive